Systems and methods for prostate treatment

• US 10,390,873 B2
• Filed: 07/26/2010
• Issued: 08/27/2019
• Est. Priority Date: 04/27/2009
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Hoey, Michael, Shadduck, John H.
• Primary Examiner(s): Della, Jaymi E
• Application Number:
  US12/843,581
• Publication Number:
  US 20100292767A1
• Time in Patent Office: 3,319 Days
• Field of Search: 606 27- 28, 606 31
• CPC Class Codes: A61B 18/04 by heating by applying electromagnetic radiation A61B18/18; hyperthermia using electric or magnetic fields, radiation or ultrasound A61N
• CPC Class Codes: A61B 2018/00011 with fluids
• CPC Class Codes: A61B 2018/00017 with gas
• CPC Class Codes: A61B 2018/00029 open
• CPC Class Codes: A61B 2018/00547 Prostate
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/1425 Needle
• CPC Class Codes: A61B 2218/005 using gas or vapor, e.g. for protection or purging

Abstract

An energy delivery probe is provided that may include any of a number of features. One feature of the energy delivery probe is that it can apply energy to tissue, such as a prostrate, to shrink, damage, denaturate the prostate. In some embodiments, the energy can be applied with a vapor media. The energy delivery probe can include a vapor delivery member configured to extend into a transition zone prostate tissue. A condensable vapor media can be delivered from the vapor delivery member into the transition zone tissue, wherein the condensable vapor media can propagate interstitially in the transition zone tissue and be confined in the transition zone tissue by boundary tissue adjacent to the transition zone tissue. Methods associated with use of the energy delivery probe are also covered.

Claims

1. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing an energy delivery member transurethrally into a transition zone tissue adjacent a patient'"'"'s prostatic urethra; and

injecting a condensable vapor media from the energy delivery member into the transition zone tissue at a depth of less than 12 mm outward from the patient'"'"'s prostatic urethra so as to confine the condensable vapor media in the transition zone tissue and to ablate the transition zone tissue adjacent to and less than 12 mm outward from the prostatic urethra, wherein the condensable vapor media is configured to apply energy ranging from 1 to 40 cal/sec to the transition zone tissue.

2. The method of claim 1 wherein the transition zone tissue adjacent the patient'"'"'s pro static urethra is ablated without ablating the patient'"'"'s prostatic urethra.

3. The method of claim 1 wherein the transition zone tissue that is ablated extends in first and second prostate lobes.

4. The method of claim 1 wherein the condensable vapor media propagates interstitially in the transition zone tissue.

5. The method of claim 4 wherein the condensable vapor media is confined in the transition zone tissue by a boundary tissue adjacent the transition zone tissue.

6. The method of claim 1 wherein the transition zone tissue that is ablated extends from a bladder neck region to a verumontanum region.

7. The method of claim 1 wherein the condensable vapor media is injected at a plurality of sites in first and second prostate lobes.

8. The method of claim 7 wherein the condensable vapor media is injected at each of the plurality of sites for 20 seconds or less.

9. The method of claim 7 wherein the condensable vapor media is injected at each of the plurality of sites for 10 seconds or less.

10. The method of claim 1 wherein the condensable vapor media is injected at a delivery pressure of less than 200 mm Hg.

11. The method of claim 1 wherein the condensable vapor media is injected at a delivery pressure ranging between 20 mm Hg and 200 mm Hg.

12. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing a probe into a prostatic urethra;

extending a vapor delivery member from the probe into a plurality of sites in a transition zone tissue of a prostate; and

delivering a condensable vapor media from the vapor delivery member at each of the plurality of sites for 20 seconds or less and confining the condensable vapor media in the transition zone tissue.

13. The method of claim 12 wherein the condensable vapor media is delivered for 10 seconds or less.

14. The method of claim 12 wherein the condensable vapor media is delivered at a delivery pressure ranging from 20 mm Hg and 200 mm Hg.

15. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing an energy delivery member into a transition tissue adjacent a patient'"'"'s prostatic urethra; and

applying energy into a plurality of transition zone sites in left and right prostate lobes with a condensable vapor media, wherein a rate of energy delivery is between 1 cal/sec and 40 cal/sec.

16. The method of claim 15 wherein the condensable vapor media is injected from the energy delivery member at a delivery pressure ranging between 20 mm Hg and 200 mm Hg.

17. A method for treating benign prostatic hyperplasia (BPH), comprising:

introducing a probe into a prostatic urethra;

extending a vapor delivery member from the probe into a transition zone tissue of a prostate at a depth of less than 12 mm outward from the prostatic urethra; and

delivering a condensable vapor media from the vapor delivery member to the transition zone tissue at a delivery pressure ranging from approximately 20 mm Hg to 200 mm Hg, wherein the condensable vapor media is configured to provide energy ranging from 1 to 40 cal/sec into the transition zone tissue.

18. The method of claim 17 wherein the condensable vapor media is delivered into the transition zone tissue for a delivery interval of less than 20 seconds.

19. The method of claim 17 wherein the condensable vapor media is delivered into the transition zone tissue for a delivery interval of less than 10 seconds.